Mineralys Therapeutics (MLYS) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 37.6% versus a loss of 41.3%. Mineralys Therapeutics is the larger company by market cap ($1.98 billion vs $1.83 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | TRVI |
|---|---|---|
| Share price | $22.38 | $12.83 |
| Market cap | $1.98B | $1.83B |
| 1-day change | +1.31% | -2.40% |
| YTD return | -39.13% | +4.95% |
| 1-year return | -41.34% | +37.59% |
| 5-year return | — | +918.60% |
| EPS (TTM) | $-4.22 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $47.65 | $20.22 |
| 52-week low | $21.46 | $9.28 |
| Distance from 52-week high | -53.03% | -36.57% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +116.71% | +119.73% |
| Average volume | 1.03M | 1.95M |
| Shares outstanding | 88.41M | 142.48M |
| Employees | 76 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed MLYS by 78.9 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
MLYS vs TRVI FAQ
Which is bigger, Mineralys Therapeutics or Trevi Therapeutics?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.98B compared with $1.83B for Trevi Therapeutics (TRVI).
Which stock has performed better over the past year, MLYS or TRVI?
TRVI returned +37.59% over the past 12 months, compared with -41.34% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.